+++
title = "ADAP Advocacy Campaign Targets Hospital Executive Compensation in 340B Drug Pricing Program"
date = "2025-10-23T07:05:30Z"
draft = false
summary = "ADAP Advocacy's new campaign highlights excessive hospital CEO compensation funded by the 340B program, raising concerns about whether the program benefits executives more than the low-income patients it was designed to serve."
description = "ADAP Advocacy launches commercial targeting 340B Drug Pricing Program reforms, exposing excessive hospital CEO compensation funded by program meant for low-income patients."
source_link = "https://www.24-7pressrelease.com/press-release/527933/adap-advocacy-airs-commercial-calling-out-excessive-executive-compensation-for-340b-eligible-hospital-ceos"
enclosure = "https://cdn.newsramp.app/banners/health-wellness-3.jpg"
article_id = 261906
feed_item_id = 22796
qrcode = "https://cdn.newsramp.app/24-7PressRelease/qrcode/2510/23/calmXbEI.webp"
source = "24-7 Press Release"
+++

<p>ADAP Advocacy has launched a new commercial as part of its ongoing campaign for reforms to the 340B Drug Pricing Program, focusing attention on what the organization describes as excessive executive compensation for CEOs at hospitals eligible for the federal program. The commercial, which asks whether the 340B program has become "too big to fail," highlights the growing disparity between hospital executive pay and the financial struggles of patients.</p><p>Brandon M. Macsata, CEO of ADAP Advocacy, stated that hospital CEOs are receiving compensation packages 200-300% higher than the nurses providing direct patient care, with much of this funding coming from a program originally designed to help low-income patients access healthcare services. "Anyone who suggests the 340B program isn't benefiting providers and their executives more than patients is being intellectually dishonest," Macsata said. "Patients learn about this level of pay and compare it to the medical debt that they're carrying, and it literally makes them sick."</p><p>The commercial is part of the broader '340B Too Big To Fail' national advocacy campaign that will continue through the end of the year. The campaign aims to draw attention to multiple issues within the healthcare system, including declining charity care from hospitals, rising healthcare executive compensation, and increasing patient medical debt. The organization has developed an <a href="https://www.adapadvocacy.org/interactive-map" rel="nofollow" target="_blank">interactive map</a> to illustrate these concerning trends across the healthcare landscape.</p><p>The 340B Drug Pricing Program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices. While intended to help safety-net providers stretch scarce federal resources, ADAP Advocacy argues the program's benefits are increasingly flowing to hospital executives rather than the vulnerable patients it was designed to serve. The organization's commercial is available for viewing online at <a href="https://youtu.be/Q8zaGIZqDp4" rel="nofollow" target="_blank">https://youtu.be/Q8zaGIZqDp4</a>.</p><p>The campaign comes amid growing scrutiny of the 340B program's implementation and whether it continues to fulfill its original mission of supporting healthcare access for low-income populations. ADAP Advocacy's efforts represent the latest in a series of calls for greater transparency and accountability in how hospitals utilize savings from the federal drug discount program. For business and technology leaders, this development signals potential regulatory changes that could impact healthcare organizations' financial models and executive compensation structures, particularly for institutions participating in government-funded programs.</p><p>The implications extend beyond healthcare to broader corporate governance discussions about executive pay ratios and the alignment of compensation with organizational mission. As the campaign gains traction through year-end, it may influence public perception of nonprofit healthcare institutions and potentially drive policy reforms affecting how federal healthcare subsidies are distributed and monitored across the industry.</p>